Antitumor therapeutics that target EGFR signaling has been developed, including gefitinib, erlotinib, and icotinib.8 High expression of EGFR is known to positively correlate with growth and progression of ovarian cancers, leading to poor prognosis in women with advanced cases.9 This evidence concerns the gene EGFR and ovarian carcinoma.